

STATE OF THE ART FACILITY DEDICATED TO ²²⁵Ac



PANTERA

IBA AND SCK CEN LAUNCH PANTERA, A JOINT-VENTURE TO PRODUCE ACTINIUM-225

IBA & SCK CEN announced the name of their joint-venture: Pantera SA/NV. This new company will aim to secure the large-scale production of actinium-225 (²²⁵Ac), one of the most promising alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, Pantera's ultimate goal is to improve the accessibility of a future innovative cancer therapy based on ²²⁵Ac.


The complementarity of IBA and SCK CEN's expertise has been demonstrated by the extensive and comprehensive R&D work that has been conducted during the last year as they work towards being able to produce large volumes of ²²⁵Ac. Pantera is now completing the technical feasibility studies before working on the final design and construction of its first facility in Mol, Belgium. Groundbreaking is expected to take place in 2024, with production starting in 2027.

Actinium-225 possesses the resounding potential to treat cancers more effectively. Initial results show that the theranostic radioisotope completely eliminates cancer cells, rather than just inhibiting tumour growth. The risk of recurrence also appears to decrease. To date, extensive research and numerous studies are underway which aim to tackle both high prevalence cancers including prostate, lung, colon, breast, pancreatic, blood (leukemia and other rare forms) and kidney cancers, but also rarer forms of cancer like glioblastoma, the deadliest form of a very invasive brain cancer.

Watch the video to know more about Pantera and how they will produce ²²⁵Ac

[WATCH THE VIDEO](#)


I am excited about the opportunity to help advance the mission of Pantera to bring a new hope for cancer patients by enabling the widespread use of radioisotopes, such as actinium-225, as a basis for promising new radiopharmaceuticals. Pantera offers 'A better fight for life', potentially bringing an effective and efficient treatment option while maximizing the quality of life of the patients, with the possibility to expand the production to other isotopes in the future.



Sven Van den Bergh
Chief Executive Officer
Pantera

SUCCESS STORIES

THE GROUND BREAKING CEREMONY (BHOOMI POOJA CEREMONY) OF THE CYCLOTRON FACILITY OF LUCKNOW IN INDIA.



The facility will soon host a state-of-the-art IBA Cyclone® KIUBE. Bhoomipooja is a ritual performed in honour of Goddess Bhoomi and Vastu Purush. Bhoomi means Mother Earth. The Purpose: This pooja is believed to eradicate the ill effects and Vastu doshas in the land and pave the way for a smooth construction.


CNRT AND IBA SIGN COLLABORATION AGREEMENT TO INSTALL A CYCLONE® IKON IN CHINA

IBA signed a collaboration agreement with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON (30 MeV cyclotron) in Chengdu, Sichuan Province, China. CNRT is a Chinese manufacturer and provider of medical isotopes used for oncology diagnosis and therapy.

The Cyclone® IKON will be used for the production of novel isotopes for use in theranostics and targeted therapies, particularly for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64. These enable the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities.

[Read full press release](#)

There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. Since its launch in 2020, this is the fourth Cyclone® IKON unit sold globally and we look forward to working with CNRT over the coming months and years.




Bruno Scutnaire
President of IBA
RadioPharma
Solutions

RIGGING OF THE CYCLONE® KIUBE AT NEIJANG



The cyclotron was rigged into HIC's vault at Neijang in China. The new radiopharmacy will soon be able to produce F-18 compounds.

CYCLONE® KIUBE RIGGING IN SINOTAU'S SITE IN WUXI, CHINA



Thanks to the new Cyclone®KIUBE, the team will soon produce F-18 and Ga-68 compounds for patient diagnosis!

Congratulations to all the people involved in this project!

IBA EXPANDS ITS ACTIVITIES IN SUB-SAHARAN AFRICA


IBA signed a new contract with Sweden Ghana Medical Centre (SGMC) for an IntegraLab® PLUS in Accra, Ghana. SGMC is a leading private cancer care center focused on providing the highest quality cancer treatment in West Africa. The contract marks IBA's increasing presence in the region with operations in 21 countries.

This contract follows several others signed in Tanzania and South Africa, and further highlights IBA's ambition to broaden access to cancer diagnostics and treatments in regions of the world with low population density and limited access to healthcare. The demand for diagnostic and therapeutic equipment in Africa is rapidly growing, with cancer

cases rising to over 800 000 cases per year in Sub-Saharan Africa.

[Read full press release](#)


IBA's technology, not only provides us with a cost efficient and user-friendly cyclotron system but also tailored solutions that meet our specific needs, allowing us to provide the best possible care to our patients.




Dr. Clement Edusa,
CEO and Medical
Director at Sweden
Ghana Medical Centre

THE CYCLONE®KIUBE WAS RIGGED FOR RABBOUD TRANSNATIONAL MEDICINE B.V. AND LIFE RADIOPHARMA.

In a few months they will start their F-18 compounds production with the Cyclone®KIUBE and Synthera®!



SITE ACCEPTANCE AT INSTITUTE FOR BASIC SCIENCE (IBS)



Only 12 month after the rigging, the Cyclone® 70 is now ready for operation! On this occasion, IBA received an appreciation plaque from IBS for the successful completion of the 70 MeV cyclotron project in South Korea.

NOVATEC INTERNATIONAL, ELSMED HEALTHCARE SOLUTIONS AND IBA HAVE SIGNED A CONTRACT FOR THE INSTALLATION OF AN INTEGRATED RADIOPHARMACEUTICALS PRODUCTION FACILITY IN TBILISI, GEORGIA.

The project will be the first of its kind in Georgia and includes the construction of an ultra-modern radiopharmaceutical facility equipped with the latest technologies such as the IBA's Cyclone® KIUBE and Synthera®+ platform. The center will produce various types of radiopharmaceutical products and is expected to start operations in 2024.

[Read full press release](#)

This unique project for an on-site production facility for radiopharmaceutical compounds will significantly boost the development of nuclear medicine in the country of Georgia. This initiative will also contribute to increasing the availability of Positron-Emission Computed Tomography (PET-CT) for a wider population. The facility will be able to fully cover the current and future demand of the Georgian market, both in terms of production and delivery of fluorodeoxyglucose (¹⁸F-FDG) as well as other artificial radioactive isotopes.

Giorgi Glonti, General Director Novatec International

CHEMISTRY

AUTOMATED CASSETTE-BASED SYNTHESIS OF [¹⁸F]FAPI-74 VIA [¹⁸F]ALF STRATEGY FOR ROUTINE PRODUCTION IN A GMP ENVIRONMENT.

Fully automated, optimized and simplified synthesis of [¹⁸F]FAPI-74 has been obtained on Synthera® with high radiochemical and chemical purity. Read the paper written by IBA, PositronPharma and Sofie.

[READ THE POSTER](#)

SYNTHERA® EXTENSION, A PLATFORM FOR THERANOSTIC RADIOPHARMACEUTICAL APPLICATIONS AND PEPTIDE LABELLING



Synthera® Extension complements the functionality of the Synthera® platform with its additional valves and a syringe driver for more complex processes such as 68Ga-peptides labelling (for both generator and cyclotron liquid target solutions). The module employs a re-usable support cassette where disposable tubing can be placed, which eliminates the need to use an additional IFPP™ for complex syntheses.


[More info](#)

DEVELOPMENT OF A [¹⁸F]AIF-NOTA-OCTREOTIDE FOR DIAGNOSIS OF NEUROENDOCRINE TUMORS ON SYNTHERA®+

R2IBF's team in Rio de Janeiro has developed a new radiopharmaceutical with the newly acquired Synthera®+; the [¹⁸F]AIF-NOTA-Octreotide.

In collaboration with Dr.Vasko Kramer, Positron Pharma-Chile, and IBA, the team has developed and optimized production process, improving synthesis and quality control protocols. Once the production protocol has been established, the process validation and stability data have been determined.

R2IBF then submitted the dossier and received its approval from the local regulatory authority to commercialize [¹⁸F]AIF-NOTA-Octreotide in August 2022. Clinical studies with [¹⁸F]AIF-NOTA-Octreotide were performed in collaboration with the Nuclear Medicine Team at INCA ([Brazilian National Cancer Institute](#)).



Forty-eight patients were examined with the new radiopharmaceutical to evaluate its efficiency and aiming to include the [¹⁸F]AIF-NOTA-Octreotide into the Brazilian Public Health system (SUS).


Since its approval, sixty-five patients have benefited from the differential diagnosis using [¹⁸F]AIF-NOTA-Octreotide. The R2IBF Team is proud to take part and help in the growth of Nuclear Medicine in Brazil.

CLOSER TO THE USERS

IBA PET CYCLONE® AND SYNTHERA® USERS MEETINGS 2022

In September 2022, IBA held the 13th IBA PET Cyclone® and our 7th Synthera® Users Meeting. After 3 years without any face-to-face meeting, we were all eager to meet and exchange.

More than 75 IBA Users attended the meeting and took this opportunity to learn and share their experiences throughout the general workshops, round-tables and presentations. This meeting was a great success with 90% of customers' general satisfaction.



It was also the occasion to celebrate customers' long-lasting relationships; Eczacıbasi Monrol AS, Ospedale San Raffaele srl and Eindhoven University of Technology with more than 20 years relationship, Clínica Universidad de Navarra and Universitätsklinikum Essen with more than 25 years as well as McGill and Austin Health with over 30 years.

We would like to thank our Users again for attending this event and we look forward to seeing the next edition in 2024 in Groningen!

[WATCH THE AFTERMOVIE](#)

IBA AROUND THE WORLD

The whole team was thrilled to be back to in-person meetings and see you all around the world to share our solutions. Here are some events where you might have seen us...

WTTC




We were happy to meet you and answer your questions about IBA's new cyclotrons; the Cyclone®IKON and the Cyclone® KEY at the 18th Workshop on Targetry and Target Facility meeting.

ASNC




We had the chance to showcase our solutions for Cardiac PET imaging at the 27th Annual meeting of the American Society of Nuclear Cardiology.

WFNMB



During the 13th WFNMB Congress, we had the pleasure to meet you and to showcase our new cyclotron for F-18 access granted, the Cyclone® KEY.



SBNM
Another great Brazilian Nuclear Medicine Conference! Many of you came to see our solutions for radiopharmaceutical productions.

DANISH RADIOCHEMISTRY MEETING



It was nice to meet you and to talk about the Synthera®+, a fully automated synthesizer for the production and purification of radioactive compounds for diagnostic imaging applications.

EANM

It was great to be back and see all of you during the EANM annual meeting! Many of you participated to the Learn&Talk sessions about radiotheranostics, Ac-225 and new tracers development. You also had the chance to see how compact the Cyclone® KEY is thanks

WHERE CAN YOU MEET US NEXT?

Our team will be happy to welcome you at our booth at :

- **OGNMB**, January 19-21, Bad Ischl, Austria
- **SNMMI Mid-Winter**, January 26-28, San Francisco, USA
- **Arab Health**, January 30 to February 02, Dubai, UAE
- **TAT12**, February 27-02, Cape Town, South Africa
- **ISTR**, April 17-21, Vienna, Austria
- **DGN**, April 19-22, Leipzig, Germany
- **BELNUC**, April 22nd, Brussels, Belgium
- **WARMTH ICRT**, May 01-05, Accra, Ghana
- **ISRS**, May 22-26, Honolulu, Hawaii
- **ANZSNM**, May 26-28, Adelaide, Australia
- **SNMMI**, June 24-27, Chicago, USA



iba-RadiopharmaSolutions.com

Sylvain Savaria
Vice President NA
Sylvain.Savaria@iba-group.com

Li Chen
Sales Director China
Chen.Li@iba-group.com

Claudia Ochoa
Vice President Western Europe & Global Chemistry Solutions
Claudia.Ochoa@iba-group.com

Peter Leitner
Vice President APAC
Peter.Leitner@iba-group.com

Ambrosio Moreno
Vice President LATAM
Ambrosio.Moreno@iba-group.com

Robert Kwizera MUGABO
Sales Area Manager EMEA
Robert.KwizeraMugabo@iba-group.com

Dmitry Cherkasov
Sales&Marketing Director Russia&CIS
Dmitry.Cherkasov@iba-group.com

Sujala Vaniyath
Chemistry Sales Manager
sujala.vaniyath@iba-group.com

IBA RadioPharma Solutions
Chemin du cyclotron, 3
1348 Louvain-la-Neuve
Belgium

Tél. : +32 10 201 275
Fax : +32 10 47 59 00
RadioPharmaSolutions@iba-group.com